Medicept's F. David Rothkopf to Illuminate Modern FDA Inspections at MEDevice Silicon Valley

Transforming FDA Inspection Protocols in 2026



In a pivotal session scheduled for November 18, 2026, at MEDevice Silicon Valley in San Jose, F. David Rothkopf, the founder of Medicept, will address medical device teams about significant changes in FDA inspections. Titled "This Is Not Your Father's FDA," the session aims to inform participants of the profound transition in inspection methods that took effect earlier this year.

The Old vs. The New: Inspection Methodology


Until February 2, 2026, the FDA employed the Quality System Inspection Technique (QSIT), a model that quality teams have relied upon since the late 1990s. With the introduction of the Quality Management System Regulation (QMSR), QSIT has been discontinued, significantly shifting the approach inspectors use today. Instead of focusing solely on prescribed methods, inspectors now delve into a company’s own risk management files, following a system-wide trail to understand potential risks to patients and users.

Rothkopf, with his extensive experience over 35 years in the field of medical device development and regulatory strategies, will guide attendees through the nuances of the current inspection landscape. He has executed over 400 ISO 13485 and FDA-style audits and established Medicept in 1996, reinforcing his insights with rich firsthand experiences. This educational talk follows his recent appearances at other MEDevice conferences, where he highlighted the pressing need for companies to adapt to these regulatory changes.

A New Focus on Risk Management


The crux of Rothkopf's presentation will detail how an FDA inspection operates today, elucidating the aspects of the review process that are critically important for compliance. Notably, the emphasis shifts towards risk management, now central not just in product design but throughout the entire inspection process. Attendees will learn what documents and records inspectors will request—records that were previously kept from scrutiny, such as management reviews, internal audits, and supplier audits.

Rothkopf argues that this fundamental shift requires teams to overhaul their inspection preparations and strategies. He anticipates significant pushback from teams accustomed to older paradigms and reminds them that knowledge of the revised regulations is key to avoiding surprises during inspections.

Practical Tools for Inspection Readiness


To complement the session, Medicept will release an Inspection Readiness Checklist tailored for the new FDA inspections. This 30-point self-assessment will enable quality teams to evaluate their compliance readiness effectively. It includes a focus on risk management, guiding teams through the essential quality system areas now under the FDA’s scrutiny and providing a scoring mechanism to measure their preparedness.

One useful exercise from the checklist encourages participants to identify a primary patient risk and trace its pathway from the initial design inputs to post-market feedback. The goal is to complete this task, including locating relevant records, in under ten minutes—testament to both efficiency and thoroughness that is demanded in today's environment.

Patients First: The Impetus Behind Change


This focus on inspection readiness is part of a larger philosophy at Medicept, which strives to be an integrated lifecycle partner for medical device companies. The firm specializes in combining regulatory, quality, clinical, and commercialization expertise to streamline operations, reducing risks and gaps in compliance and thereby accelerating the delivery of innovations to patients.

As Rothkopf states, “Patients are waiting, ” reinforcing the urgency for quality teams to prepare adequately for inspections, ensuring continuous alignment throughout the product development lifecycle. With clients ranging from novice start-ups seeking direction to established enterprises aiming for sustainable operations, Medicept is poised to guide them through modern challenges.

Join Us at MEDevice Silicon Valley


For those attending MEDevice Silicon Valley, Rothkopf’s session is scheduled for 10:45 AM PST at the Design Studio Theater (805). It promises to be a valuable opportunity to rethink and revamp FDA inspection approaches, updated for the new regulatory landscape.

To further engage with the Medicept team and discover how to prepare effectively for upcoming inspections, attendees can visit medicept.com/contact. Through its commitment to empowering quality teams, Medicept stands ready to assist the medical device community in navigating these new waters of compliance and regulation.

The Future of FDA Inspections Begins Now


As the medical device landscape continues to evolve, Rothkopf’s insights will be critical in shaping how companies prepare for FDA inspections in the future. Adapting to these changes without delay will ensure a more robust approach, ultimately leading to improved patient care and device efficacy.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.